RxDoctor Payments DataLook up a doctor →

Jawad Zafar, DO

Psychiatry · Beckley, WVNPI 1922427376

Payments from drug & device makers

$14,870in general payments, 2019–2025

Across 622 payments — averaging $23.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$5K
  • AbbVie$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Otsuka America Pharmaceutical, Inc.$1000
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$744
  • Pfizer$688
  • plus $6K from 34 others

What the payments were for

  • Speaking & faculty fees$2,30015%
  • Travel & lodging$1,47110%
  • Food & beverage$10,52171%
  • Education$5784%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,870 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Medicare billing

Part B allowed, 2024
$127,820
Medicare patients
163
Services billed
973

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl31$58,305
RexultiBrexpiprazole37$47,710
TrintellixVortioxetine Hydrobromide16$14,994
Lurasidone Hcl67$14,842
Aripiprazole130$11,686
VyvanseLisdexamfetamine Dimesylate28$9,794
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl114$9,541
Vilazodone Hcl54$5,865
Memantine Hcl ErMemantine Hcl90$4,850
Venlafaxine Hcl ErVenlafaxine Hcl65$3,865
Duloxetine Hcl218$3,671
Trazodone Hcl356$2,643
ZubsolvBuprenorphine Hcl/Naloxone Hcl12$2,421
Desvenlafaxine Succinate ErDesvenlafaxine Succinate60$2,342
Buspirone Hcl195$2,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,162$58,30531 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,000$47,71037 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$576$24,78844 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$21$9,541114 claims
Lilly USA, LLCOlanzapine$178$1,03961 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Beckley

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →